Back to basics: do we need more immuno-oncology in the core curriculum?
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing
According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines
Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
CheckMate 722 trial fails to meet its primary endpoint in patients with cancer progressing on one or two prior lines of EGFR tyrosine-kinase inhibitors
Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach
An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.